Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Ralzapastotug Biologics Sequence Review Report 2026: TIGIT Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ralzapastotug, an antibody targeting TIGIT.
Read →
Latest Hotspot
8 min read
Prafnosbart Biologics Sequence Review Report 2026: ACVR1 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Prafnosbart, an antibody targeting ACVR1.
Read →
Latest Hotspot
8 min read
Pradusinstobart Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pradusinstobart, an antibody targeting PD-1.
Read →
Latest Hotspot
8 min read
Patecibart Biologics Sequence Review Report 2026: EDNRA Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Patecibart, an antibody targeting EDNRA.
Read →
Latest Hotspot
8 min read
Ozekibart Biologics Sequence Review Report 2026: TNFRSF10B Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ozekibart, an antibody targeting TNFRSF10B.
Read →
Latest Hotspot
8 min read
Obertamig Biologics Sequence Review Report 2026: CD3E × HLA-G Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Obertamig, an antibody targeting CD3E × HLA-G.
Read →
Latest Hotspot
8 min read
Lipustobart Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lipustobart, an antibody targeting PD-1.
Read →
Latest Hotspot
8 min read
Epacmarstobart Biologics Sequence Review Report 2026: SIRPA Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Epacmarstobart, an antibody targeting SIRPA.
Read →
Latest Hotspot
8 min read
Ciduvectamig Biologics Sequence Review Report 2026: TMEFF2 × CD3E Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ciduvectamig, an antibody targeting TMEFF2 × CD3E.
Read →
Latest Hotspot
8 min read
Uprevstobart Biologics Sequence Review Report 2026: CD73 Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Uprevstobart, an antibody targeting CD73.
Read →
Latest Hotspot
8 min read
Solrikitug Biologics Sequence Review Report 2026: TSLP Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Solrikitug, an antibody targeting TSLP.
Read →
Latest Hotspot
8 min read
Samatatug Biologics Sequence Review Report 2026: Tissue factor Similarity and Patent-Risk Signals
3 August 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Samatatug, an antibody targeting Tissue factor.
Read →
<
1
<<
1813
1814
1815
1816
1817
>>
2926
>